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Rapid communication
Telomerase activity in human pleural
mesothelioma
Karl Dhaene, Roland Hübner, Samir Kumar-Singh, Barbara Weyn, Eric Van Marck
Abstract
Background—Gradual telomere erosion
eventually limits the replicative life span of
somatic cells and is regarded as an ultimate
tumour suppressor mechanism, eliminat-
ing cells that have accumulated genetic
alterations. Telomerase, which has been
found in over 85% of human cancers, elon-
gates telomeres and may be required for
tumorigenesis by the process of immortali-
sation. Malignant mesothelioma is an in-
curable malignancy with a poor prognosis.
The disease becomes symptomatic decades
after exposure to carcinogenic asbestos
fibres, suggesting the long term survival of
pre-malignant cell clones. This study in-
vestigated the presence of telomerase in
pleural malignant mesothelioma, which
may be the target for future anti-telo-
merase drugs.
Methods—Telomerase activity was semi-
quantitatively measured in extracts from
22 primary pleural mesotheliomas, two
benign solitary fibrous tumours of the
pleura, four mesothelioma cell lines, and
six short term mesothelial cell cultures
from normal pleura using a non-isotopic
dilution assay of the telomeric repeat
amplification protocol.
Results—Twenty of the 22 primary meso-
theliomas (91%) and all tumour derived
mesothelioma cell lines were telomerase
positive. DiVerent levels of enzyme activ-
ity were observed in the tumours of diVer-
ent histological subtypes. Telomerase
activity could not be detected in the six
normal mesothelial cell cultures or in the
two mesotheliomas. Both benign solitary
fibrous tumours showed strong telomer-
ase activity.
Conclusions—Telomerase activity is
found in a high proportion of mesothelio-
mas and anti-telomerase drugs might
therefore be useful clinically. The results
are consistent with the hypothesis that telo-
merase activity may be a feature of
carcinogenesis in mesotheliomas and pos-
sibly in many other cancers.
(Thorax 1998;53:915–918)
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Telomeres are stretches of repetitive non-
coding DNA sequences (TTAGGG) associated
with specific DNA binding proteins at the ends
of eukaryotic chromosomes. Human telomeres
progressively shorten during cell division be-
cause DNA polymerase cannot replicate the
end of a linear template, and critical shortening
is believed to limit the cellular life span. A pos-
sible explanation for the attrition of human
telomeric buVers is the somatic repression of
telomerase. This ribonucleoprotein reverse
transcriptase can synthesise telomeric repeats at
chromosomal ends using its catalytic subunit
(hTRT) and a short template element of an
integral RNA (hTR). The “telomeric repeat
amplification protocol” (TRAP) assay has been
developed to detect the activity of the enzyme.
Telomerase activity has been found in germ
cells and in stem cells, and in a variety of cell
lines and malignant tumours, but only weak or
no activity was found in mortal somatic cell
cultures and in benign tumours.1 It has recently
been shown that forced expression of hTRT in
telomerase negative cells resulted in reconstitu-
tion of telomerase activity, elongation of telo-
meres, and extension of replicative life span.2
These data indicate a causal relationship
between telomere erosion and cellular replica-
tive senescence and suggest that this mech-
anism acts as an ultimate powerful tumour sup-
pressor system which creates a barrier to any
cell that has accumulated genetic alterations
and escaped normal growth control by its envi-
ronment. The data further lead to the specula-
tion that telomerase may be required for the
eYcient growth of neoplastic cells and that
inhibition of telomerase activity could represent
a new therapeutic approach for cancer.3 Since it
still is unclear whether telomerase activity com-
monly occurs in most tumours, we investigated
telomerase activity in malignant mesothelioma.
This cancer is a highly aggressive malignancy,
thought to arise from mesothelial cells, which is
resistant to treatment. It is characterised by an
extremely long latency period (20–40 years)
between exposure to asbestos, a major con-
tributory factor in the development of this can-
cer, and the onset of disease symptoms, which
suggests the long term survival of genetically
altered cell clones.4
In this study we have investigated whether
mesothelioma shares telomerase activity with
other cancers and we further report the
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absence of telomerase activity in somatic meso-
thelial cell cultures.
Methods
TISSUES AND CELLS
Specimens of 22mesotheliomas (nine epithelial,
four sarcomatous, nine mixed types) and of two
benign solitary fibrous tumours of the pleura
were snap frozen in liquid nitrogen at the time of
pleuroscopy and stored at –80°C. Short term
mesothelial cell cultures were established from
stripped pleura from necropsied non-cancerous
patients after trypsin disaggregation. Mesothe-
lial cells were grown as primary cultures on
fibronectin coated culture flasks in RPMI 1640
supplemented with 20% heat inactivated fetal
bovine serum (Gibco BRL, Belgium) and
10 ng/ml hydrocortisone (Upjohn, Belgium).
The cells were identified as mesothelial cells by
several criteria including immunocytochemical
staining with antikeratin antibodies (Dako,
Glostrup, Denmark), cell morphology (cobble-
stone), and the presence of long microvilli
observed by transmission electron microscopy.
Third passage confluent cultures grown at 37°C
and 5% CO2 were harvested for TRAP analysis.
Malignant mesothelioma cells were obtained
from four human mesothelioma cell lines
(UIA-MM 1, 2, 5 and 7) which were isolated
from pleural fluid as described elsewhere.5 The
Jurkat cell line served as a positive control.
NON-ISOTOPIC TRAP ASSAY
Lysate preparation and the TRAP assay were
performed as described by Kim et al6 with minor
modifications. Briefly, homogenates of frozen
sections (100 mm3) and cell pellets (106 cells)
were prepared with disposable pestles in 200 µl
ice cold lysis buVer. After 30 minutes of incuba-
tion on ice the lysates were centrifuged at
14 000g for one hour at 4°C and the protein
concentration of the supernatant measured
according to Bradford (Bio-Rad Protein Assay,
Bio-Rad Laboratories GmbH, Germany). Ali-
quots of a dilution series of each lysate (6 µg,
0.6 µg, and 0.06 µg of total protein) were used
for the TRAP assays. After initial incubation at
23°C for 30 minutes telomerase products were
amplified using TS and ACX primers (35 cycles
at 94°C for 30 s, 53°C for 30 s, and 72°C for 30
s). Assay specificity was confirmed by inclusion
of an RNase pre-incubation control step. The
presence of Taq polymerase inhibitors in cases
lacking the 6 bp ladder was assessed using the
TSNT internal control oligonucleotide and the
NT internal control primer, generating a 36 bp
control band. PCR products were separated by
electrophoresis on a 12.5% non-denaturing
polyacrylamide gel (19:1). The gel was stained
with ethidium bromide or SYBR green I nucleic
acid gel stain (FMC, BioProducts, Rockland,
Maine, USA) and analysed by the CCD camera
coupled Gel Doc 1000 Molecular Analyst Soft-
ware package (Bio-Rad). Telomerase activity
was graded as negative (6 bp ladder not
detected), weakly positive (ladder detected with
6 µg protein), moderately positive (ladder de-
tected with 6 or 0.6 µg protein but not with
0.06 µg), or strongly positive (ladder detected at
all three protein concentrations).
Results
In a preliminary experiment the sensitivity of
our ethidium bromide based procedure was
compared with an assay in which we stained
the amplified telomerase products with SYBR
green I that is known to be as sensitive as clas-
sical isotopic TRAP assays.7 One hundred tel-
omerase positive Jurkat cells were found to be
suYcient for the detection of telomerase activ-
ity in the study using SYBR green. Similar sen-
sitivity was observed in the ethidium bromide
based assay (data not shown).
Representative results for serial dilutions of
extracts of the analysed materials are shown in
fig 1. The TRAP assay was performed with the
Figure 1 Representative results of non-isotopic TRAP assays for serial dilutions of extracts from mesothelioma tumour samples
(MM4,MM11 and MM16),mesothelial cells (MC1), and one solitary fibrous tumour (SFT1). Jurkat cell extracts (J)
served as positive control (a). For every assay a 36 bp internal control band is visible (arrow).Each sample analysis contained
an RNase A treated control (+ at top) showing loss of signal. Lysis buVer alone (LB) was applied as negative control (g).
PCR products were separated by electrophoresis on a non-denaturing 12.5% polyacrylamide gel, stained with ethidium
bromide, and visualised on a UV transilluminator. The assay result is indicated at the bottom of the figure. Telomerase activity
(TA) was semi-quantitatively estimated and was graded strong (b),moderate (c),weak (d) or absent (e).
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use of 6 µg protein extracts and varying levels
of telomerase activity were observed in 20
(91%) of 22 mesotheliomas, in all four cancer
cell lines, and in both solitary fibrous tumours.
Signals were abolished after pre-incubation
with RNase A. Because the signal intensities
varied among samples, we estimated telomer-
ase activity by dilution assay using 10-fold
(0.6 µg) and 100-fold (0.06 µg) diluted ex-
tracts. Five of 20 telomerase positive mesothe-
liomas retained signals after the 10-fold
dilution (panels b and c) and two of these
retained signals after the 100-fold dilution
(panel b), indicating that these tumours
expressed high levels of telomerase activity.
High levels of activity were also observed after
10-fold and 100-fold dilution of the extracts of
both solitary fibrous tumours (panel f). The
dilution assay could not detect any telomerase
activity in the mesothelial cells (panel e) nor in
mesothelioma cases MM2 and MM21. False
negativity caused by Taq polymerase inhibitors
was excluded since 36 bp control products
were amplified in all TRAP assays. Table 1
summarises the results of the dilution assays of
mesotheliomas and solitary fibrous tumours
according to signal intensity and histology. No
statistical analysis was performed because of
the small size of the study.
Discussion
The finding of telomerase activity in over 90%
of mesotheliomas is in agreement with the
reported activity in a variety of other cancer
types. This result is consistent with the hypoth-
esis that telomerase activity may be a feature of
carcinogenesis in mesothelioma and also, per-
haps, in many other cancers. Carcinogenesis is
recognised as a multistep process resulting from
the accumulation of sequential genetic altera-
tions in a cell. The very long latency period
characteristic of mesothelioma suggests that
multiple cumulative genetic, cytotoxic, and
proliferative events occur during the tumori-
genic conversion of the progenitor cell. Of the
known changes that we and others have investi-
gated in mesothelioma, the most frequent are in
the p16 and NF2 genes.8 According to the
telomere senescence model, such genetically
altered pre-malignant cells may finally be elimi-
nated before they can ever develop a full blown
malignant phenotype. Conversely, the presence
of telomerase activity in mesothelioma may
indicate that these cells can overcome the
restraint of their finite life span and are no
longer hampered in their clonal evolution
towards a more malignant phenotype. In view
of the finding of telomerase activity in mesothe-
lioma, anti-telomerase drugs might be useful
clinically. However, telomerase activity could
not be detected in the lysates of twomesothelio-
mas. It has been reported that some tissue sam-
ples contain an inhibitor of Taq polymerase and
thus give a false negative result.6 The successful
co-amplification in our cases of the TRAP
internal control excluded this possibility. At
present we therefore cannot exclude the possi-
bility that some mesotheliomas have telomere
stabilising mechanisms that are independent of
telomerase, or are not immortal at all. This cer-
tainly would weaken the eYcacy of future anti-
telomerase drugs.
We did not detect telomerase activity in
mesothelial cells. There is considerable evi-
dence that mesothelioma originates from
surface mesothelial cells rather than from a
“multipotential” subserosal stem cell, although
this has not been established beyond all doubt.4
Assuming the former scenario is correct, the
absence of detectable telomerase activity in
mesothelial cells, in contrast to the presence of
activity in mesotheliomas, could fit with the
interpretation that most adult tumours develop
from telomerase negative precursors after
telomerase re-activation.9 On the other hand,
others may interpret these results as evidence
for the above mentioned stem cell origin of
mesothelioma, arguing that these telomerase
positive tumours do, indeed, arise from telo-
merase positive stem cells without the need for
a re-activation step.10
The strong telomerase activity detected in
both benign solitary fibrous tumours may sup-
port the hypothesis of their origin from telo-
merase positive, CD34 positive fibroblastic
stem cells or suggest unpredictable clinical
behaviour. Similarly, Umbricht et al11 found
19% of benign follicular tumours of the thyroid
with detectable telomerase activity and argued
that some histologically benign lesions may be
precursor lesions of follicular carcinomas. Our
observations may also indicate that the use of
telomerase activity as a marker for malignancy
of serosal lesions needs further validation. It is
obvious that larger series need to be studied,
which should also include unequivocal benign,
mesothelium derived tumours such as adeno-
matoid tumours.
The “classic model” states that telomerase
upregulation is forced by critical telomere ero-
sion beyond the point where cell multiplication
normally stops. An in vitro situation is seen
during continuous culture of SV40 large T
Table 1 Telomerase activity profiles of individual
mesotheliomas and solitary fibrous tumours in relation to
histological subtype
Tumours Histological subtype 6* 0.6* 0.06*
MM1 Epithelial + − −
MM2 Epithelial − − −
MM3 Epithelial + − −
MM4 Mixed + − −
MM5 Mixed + − −
MM6 Sarcomatous + − −
MM7 Sarcomatous + − −
MM8 Epithelial + − −
MM9 Epithelial + − −
MM10 Mixed + − −
MM11 Epithelial + + −
MM12 Mixed + − −
MM13 Mixed + − −
MM14 Mixed + − −
MM15 Epithelial + − −
MM16 Mixed + + +
MM17 Sarcomatous + + −
MM18 Mixed + + −
MM19 Mixed + − −
MM20 Epithelial + − −
MM21 Sarcomatous − − −
MM22 Epithelial + + +
SFT1 Benign + + +
SFT2 Benign + + +
MM=malignant mesothelioma; SFT = solitary fibrous tumour.
*Amounts of protein extracts (in µg) applied per TRAP assay
reaction.
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antigen transformed telomerase negative hu-
man cells which eventually undergo “crisis”
—the condition in which cellular chromosomes
are characterised by ultrashort telomeres and
that coincides with telomerase activity.12 At
present it is not known whether SV40-like
viruses, for which DNA sequences have been
found in some mesotheliomas, are responsible
for an in vivo equivalent of crisis during
mesothelioma carcinogenesis.13
The“co-selectionhypothesis”states that telo-
merase is indirectly re-activated as part of a
“package” of changes in gene expression that
occurs after some other genetic event.14 It
remains speculative whether asbestos induced
DNA damage represents such a genetic event.
Similarly, others have suggested that telomer-
ase activation is a mere side eVect of de-
diVerentiation.15 We observed diVerent levels of
enzyme activity in the tumours of diVerent his-
tological subtypes. Because of the limited size
of the study we did not perform statistical
analysis to find any correlation between the
level of telomerase activity in the tissue lysates
and the histological subtype. In any case,
statistical analysis may be inaccurate because of
weaknesses in the TRAP assay. Indeed, both
heterogeneity of tumour diVerentiation within
a tissue section and its morphology are lost
during an in vitro biochemical assay, indicating
the need for alternative methods for detecting
telomerase activity at the cellular level. In situ
hybridisation techniques with probes directed
against hTRT mRNA and hTR, together with
immunohistochemistry using antibodies to the
various subunits of the holo-enzyme, may help
in the further investigation of the expression of
telomerase in benign and malignant pleural
lesions.
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